BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025.
Canaccord Genuity 45th Annual Growth Conference
Fireside Chat Date: Tuesday, August 12, 2025
Fireside Chat Time: 4:30 PM ET
Location: Boston, MA
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Contacts:
Media:
Natalie St. Denis
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-720-925-9285
Investors:
Chris Brinzey
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-339-970-2843
| Last Trade: | US$0.43 |
| Daily Change: | 0.03 7.24 |
| Daily Volume: | 1,116,661 |
| Market Cap: | US$62.290M |
August 07, 2025 May 22, 2025 May 15, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
